Skip to main content
Psych Congress  

Transcranial Magnetic Stimulation for the Treatment of Major Depressive and General Anxiety Disorders: A Retrospective Evaluation of Clinical Outcomes in a Private Practice Setting

Authors  
Kimberly Cress, MD.
Sponsor  
TMS Serenity Center

Transcranial Magnetic Stimulation for the Treatment of Major Depressive and General Anxiety Disorders: A Retrospective Evaluation of Clinical Outcomes in a Private Practice Setting
Kimberly Cress MD1
1TMS Serenity Center, Sugar Land, Texas.
Objective: Major depression with comorbid general anxiety disorders is a common condition associated with poor outcomes. This retrospective evaluation was designed to evaluate the potential efficacy of high-frequency repetitive transcranial magnetic stimulation (rTMS) in patients with major depression and general anxiety disorders treated in a private practice setting.
Methods: 72 patients with a primary or secondary diagnosis of major depression and general anxiety disorders, who had previously failed to receive benefit from pharmacotherapy, received NeuroStar® rTMS treatment in a private practice setting. Patients were assessed pre and post treatment using the Beck Depression Inventory (BDI) scale, Beck Anxiety Inventory (BAI) scale and the Patient Health Questionnaire (PHQ-9) depression scale. Mean clinical outcomes were evaluated retrospectively to assess post-acute phase efficacy and safety of treatment.
Results: 49 females and 23 males, with an average age of 48.9 ± 12.9 years, were treated with rTMS. The mean BDI symptom score at baseline was 26 ± 10.8 and improved to 9.3 ± 7.7 at the end of the acute phase of treatment (mean 37.8 ± 13.0 treatments). BAI symptom scores improved from a mean of 16.6 ± 10.9 at baseline to 7.6 ± 8.5 at the end of the acute phase of treatment and mean PHQ-9 baseline symptom scores went from 16.7 ± 6.8 to 5.2 ± 4.9 at the end of the acute phase of treatment. There were no significant adverse events identified. 
Conclusion: In a private practice setting rTMS demonstrates significant clinical improvements in major depressive and general anxiety symptomatology.

Back to Top